ARCT

Arcturus Therapeutics Holdings Inc. (ARCT) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Arcturus Therapeutics is a commercial messenger RNA (mRNA) medicines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines. The company recently transitioned to a commercial stage with the approval and sale of its self-amplifying mRNA (sa-mRNA) vaccine, KOSTAIVE (ARCT-154), in Japan and the European Union.

Key Financial Metrics

Liquidity & Debt: The company holds $196.5 million in cash and cash equivalents and $56.9 million in restricted cash. It maintains a $50.0 million revolving credit facility with Wells Fargo, which was amended in June 2024 to extend the term to April 2026. No amounts were drawn on this facility during Q2 2025.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 43% in Q2 2025 and 34% for the six months ended June 30, 2025, compared to the prior year. This was primarily due to reduced revenue from the CSL Seqirus collaboration as the KOSTAIVE program transitions from development to commercialization, resulting in less amortization and supply agreement revenue.
• Expense Reduction: Total operating expenses decreased 44% in Q2 and 38% for the six-month period. Research and Development (R&D) expenses dropped 50% in Q2, driven by lower manufacturing and clinical costs for the LUNAR-COVID program and reduced payroll. General and Administrative (G&A) expenses fell 16% in Q2, largely due to reduced share-based compensation.
• Improved Loss Profile: Despite lower revenue, the net loss narrowed significantly (47% reduction in Q2 and 47% reduction for the six months) due to the substantial decrease in operating expenses.

Guidance, Outlook, and Risks

• Commercial Milestones: KOSTAIVE received marketing authorization in the EU in February 2025 and a marketing authorization application was filed in the UK in June 2025. Sales in Japan began in October 2024.
• Therapeutic Pipeline:
  • ARCT-810 (OTC Deficiency): Positive multiple-dosing data announced in June 2025 from Phase 2 studies in Europe and the U.S., showing significant decreases in glutamine levels and increased ureagenesis function.
  • ARCT-032 (Cystic Fibrosis): Phase 2 enrollment is ongoing in the U.S.
  • LUNAR-H5N1: Phase 1 recruitment completed in April 2025; received FDA Fast Track Designation.
• Legal Proceedings: On May 30, 2025, Arcturus initiated arbitration against CSL Seqirus regarding a milestone payment triggered by the EU approval of KOSTAIVE. CSL Seqirus has contested the obligation to pay. The arbitration is ongoing.
• Internal Controls: The company disclosed a material weakness in internal control over financial reporting related to Information Technology General Controls (ITGCs), specifically regarding user access, program change management, and IT operations. Remediation is ongoing and expected to be completed in fiscal year 2025.
• Outlook: Management believes current cash resources are sufficient to fund operations for at least the next 12 months. Future funding requirements depend on milestone achievements, regulatory approvals, and potential additional financing.

Key Facts for Investor Verification

• Arbitration Outcome: Monitor the status of the arbitration with CSL Seqirus regarding the EU milestone payment, as this could impact future revenue recognition and partnership dynamics.
• Remediation of Material Weakness: Verify the progress of the remediation plan for the ITGC material weakness to ensure future financial reporting reliability.
• Commercial Sales Trajectory: Track actual sales volumes and royalty/milestone triggers for KOSTAIVE in Japan and the EU to assess the transition from development revenue to commercial revenue.
• Cash Burn Rate: Review the net cash used in operating activities ($40.9M for six months) against the cash balance ($253.4M) to confirm the runway for ongoing clinical trials (ARCT-810, ARCT-032) without immediate dilution.
• BARDA Grant Utilization: Confirm the remaining available funding ($32.2M) and the pace of revenue recognition under the BARDA contract for the H5N1 vaccine program.